

#### Value creation through profitable growth Berenberg US Conference 2018, Tarrytown Lars Rasmussen, President & CEO



Coloplast A/S - Ostomy Care / Continence Care / Wound & Skin Care / Urology Care




### **Forward-looking statements**


The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements are based on Coloplast's current expectations, estimates and assumptions and based on the information available to Coloplast at this time.

Heavy fluctuations in the exchange rates of important currencies, significant changes in the healthcare sector or major changes in the world economy may impact Coloplast's possibilities of achieving the long-term objectives set as well as for fulfilling expectations and may affect the company's financial outcomes.



## Coloplast has four business areas all with global sales presence








### **Coloplast specializes in intimate healthcare needs**

	Who are our typical users	How do we help them?	
Ostomy Care	People who have had their intestine redirected to an opening in the abdominal wall	<b>SenSura</b> <sup>®</sup> Mio Ostomy bag	
Continence Care	People in need of bladder or bowel management	<b>SpeediCath</b> ® Flexible male urinary catheter	
Urology Care	People with dysfunctional urinary and reproductive systems	<b>Titan</b> ® OTR Penile implant	
Wound Care	People with difficult-to-heal wounds	<b>Biatain<sup>®</sup> Silicone</b> Foam wound dressing	Interest "Glower Inte



# Intimate healthcare is characterized by stable industry trends





# Coloplast has strong market positions in Europe and great commercial potential outside Europe

Ostomy	Continence	Urology	Wound Care
	12.12bs		18-20bn
4-5%	5-6%	3-5%	2-4%
40 - 50%	45 - 55%	10 - 20%	5 - 15%
<b>15 - 25%</b> 35 - 45%	<b>20 - 30%</b> 20 - 30%	<b>5 - 15%</b> 5 - 10%	<b>0 - 10%</b> 10 - 20%
35-40%	~40%	~15%	7-9%
ConvaTec	Wellspect BANRID WHOIlister	ETHICON Science for life"	Since the are
<ul> <li>Ageing population</li> <li>Increasing access to healthcare</li> <li>Health care reforms</li> <li>Re-use of products outside</li> </ul>	<ul> <li>Ageing population</li> <li>IC penetration potential</li> <li>Up-selling</li> <li>Health care reforms</li> <li>Commoditization</li> </ul>	<ul> <li>Ageing, obesity</li> <li>Underpenetration</li> <li>Cost consciousness</li> <li>Clinical requirements</li> <li>Less invasive/office</li> </ul>	<ul> <li>Ageing, obesity, diabetes</li> <li>New technologies</li> <li>Healthcare reforms</li> <li>Competition</li> <li>Community treatment</li> </ul>
	40 - 50% 15 - 25% 35 - 45% 35-40% Convale Electronic Convale Electronic Convale	40 - 50%       45 - 55%         15 - 25%       20 - 30%         35 - 45%       20 - 30%         35-40%       ~40%         Vellopect         Econvertee (intermediation)         increasing access to healthcare       - Ageing population         • Ageing population       • Ageing population         • Up-selling       • Up-selling	Image: conversion of the convers

COIODIUSL

Coloplast A/S - Ostomy Care / Continence Care / Wound & Skin Care / Urology Care

Long-term guidance for the LEAD20 strategy period aimed at accelerating growth and long-term value creation







### Growth acceleration to be driven through two key pillars and GOP4 will continue to drive unparalleled efficiency



#### Two pillars to drive growth

- I. Accelerated organic investments
  - I. Invest up to 2% of topline p.a. in new incremental investment cases (R&D and commercial investments)
  - II. Emerging markets, US, selected countries in Europe
- II. Active pursuit of inorganic opportunities to strengthen our service offering towards consumers


#### **Unparalleled efficiency**

I. Global Operations Plan 4 to improve EBIT margin by 150bp with full effect from 2020/21<sup>1</sup>



<sup>1)</sup> Based on EBIT FY2016/17

# Coloplast delivered Q2 organic growth of 8% and upgraded FY organic growth guidance from ~7% to 7-8%



#### Q2 Highlights

- Q2 organic growth of 8% (4% in DKK)
  - Negative FX impact from USD/DKK. Acquisitions contributed 1% to growth
- Strong momentum in Chronic Care driven by new products and improved momentum in Emerging markets
- Wound Care organic growth improved to 8% in Q2 despite the continued negative impact from price reform in Greece
- Launch of SpeediCath<sup>®</sup> Flex Coudé Pro in May specifically designed for the US market. SenSura<sup>®</sup> Mio Concave now launched in 7 markets
- Q2 EBIT margin of 30% in constant exchange rates and 30% in reported terms (DKK)
- Interim dividend of DKK 5.0 per share
- Updated financial guidance for 2017/18:
  - Organic revenue growth of 7-8% vs. previously ~7% and ~6% in DKK vs. previously 5-6%, assuming:
    - Negative DKK 50m vs. previously DKK 100m from patent expiry
    - Negative DKK 100m from Greek price reform
  - Unchanged EBIT margin of 31-32% in constant exchange rates and ~31% in DKK




# Upgraded organic and reported growth guidance for FY 2017/18

	Guidance 2017/18	Guidance 2017/18 (DKK)*	Key assumptions
Sales growth	7-8% from ~7% (organic)	~6% from 5-6%	<ul> <li>Negative impact of DKK 50m from patent expiry</li> <li>More than 1% negative price pressure of which DKK 100m from price reform in Greece</li> <li>DKK guidance includes growth from Comfort Medical in Q1 and Lilial in Q2-Q4</li> </ul>
EBIT margin	31-32% (constant exchange rates)	~31%	<ul> <li>Impact from patent expiry and Greece</li> <li>Incremental investments of up to 2% of revenue</li> <li>DKK 20m from reduction in DK production employees</li> <li>Includes Comfort Medical and Lilial</li> </ul>
CAPEX (DKKm)		~700	<ul> <li>Factory expansion in Nyírbátor</li> <li>New machines for new and existing products</li> <li>Land acquired for new factory in Costa Rica</li> </ul>
Tax rate		~23%	

\*DKK guidance is based on spot rates as of April 30th



# We continue to provide attractive cash returns despite large investments in commercial and expansion activities



#### Comments

- Coloplast returns excess liquidity to shareholders in the form of dividends and share buy-backs
- Dividend is paid twice a year after the half-year and full-year financial reporting
- Total dividend of DKK 15.0 per share for 2016/17
- H1 2017/18 interim dividend of DKK 5.0 per share for a total interim dividend of DKK 1,060m
- DKK 1bn share buy-back program to be completed before 2018/19 fiscal year end
  - First part of the share buy-back program of DKK 500m initiated in Q2
  - Shares worth DKK 198m bought back in Q2



1) Dividends paid out in the year are the actual cash payments of which the majority relates to dividend proposed in the previous financial year 2) Pay-out ratio calculated as dividend proposed in the financial year/Net profit for the financial year. Pay-out ratio for 2013/14, 2014/15 and 2015/16 is before special items related to Mesh litigation

Page 11



## **Coloplast Capital Market Day 2018**

18 September 2018 in Copenhagen – SAVE THE DATE!

The purpose of the event is to provide institutional investors and financial analysts with the opportunity to get an update on the business and insights into key strategic themes. Please contact <u>dkasso@coloplast.com</u> to register.



## **Our mission**

Making life easier for people with intimate healthcare needs

### **Our values**

Closeness... to better understand Passion... to make a difference Respect and responsibility... to guide us

#### Our vision

Setting the global standard for listening and responding

